ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 248

Disease Severity and High Attack Frequency Under Colchicine Treatment Is Associated with Increased Carotid Intima Media Thickness in FMF

Murat Karabacak1, Ali Ugur Unal2, Gulsen Ozen3, Zeynep Erturk4, Yasemin Yalcinkaya3, Zeynep Komesli1, Nevsun Inanc3, Pamir Atagunduz3 and Haner Direskeneli5, 1Marmara University Faculty of Medicine, Istanbul, Turkey, 2Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 3Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 5Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Familial Mediterranean fever and intima medial thickness

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular (CV) risk assessment is infrequently performed in Familial Mediterranean Fever (FMF), an autoinflammatory disorder with only acute attacks of inflammation. As a surrogate marker of atherosclerosis, carotid intima media thickness (cIMT) is shown to be increased in FMF in previous studies, but the association of cIMT with traditional cardiovascular risk scores is not explored. In this study we aimed to investigate cIMT in FMF and show its relationship to traditional cardiovascular risk scores, disease severity and attack frequency.

Methods: In this cross sectional study, consecutive FMF patients (n=60, M/F: 30/30, mean age= 36.5±9.7 years) were compared to healthy controls (n=60, M/F: 29/31, mean age= 36.8±8.7 years). 10-year CV risk was assesed by 2013 American College of Cardiology/American Heart Association (ACC/AHA) CV risk estimator. FMF severity score-2 (F-SS-2) score was implemented to FMF patients to determine disease severity. Genetic mutations of FMF patients were also recorded.

Results: M694V was positive in 63% of FMF patients, either homozygote, heterozygote or compound heterozygote. 48% of FMF patients had mild, 22% had intermediate and 30% had severe disease according to F-SS-2. Groups were similar in demographic, clinical and biochemical parameters, except for sedimentation rate which was 10±4 mm in control group and 18±11 mm in the FMF group (p< 0.001). ACC/ AHA risk scores were similar in both groups: 2.5±2.9) in FMF patients vs. 2.4±2.1 in controls (p= 0.93). However, median cIMT was significantly higher in the FMF group compared to controls (FMF: 0.59 mm (IQR= 0.17) vs Controls: 0.52 mm (IQR= 0.13), p= 0.002). Patients with severe disease had a higher mean cIMT of 0.62±0.09 mm than those with non-severe disease (0.57±0.09 mm (p= 0.045). In multiple regression analysis for all participants, only age and CRP positivity are significantly associated with CIMT (p< 0.001 and p= 0.001 respectively). In the FMF group, attack frequency while on colchicine treatment (rho= 0.40, p= 0.002) correlated with CIMT, whereas attack frequency before starting colchicine was not associated (r= 0.08, p= 0.53).

Conclusion: cIMT was significantly increased in FMF, but traditional cardiovascular risk scores failed to reflect this change. Attack frequency, which may reflect unsuppressed inflammation, may contribute to the increased cIMT. Therefore, our data suggests that FMF patients, especially those with high attack frequency and severe disease, should be monitored more closely for ischemic CV disease. Further studies are also required to clarify whether better disease control leads to improved cIMT levels.


Disclosure: M. Karabacak, None; A. U. Unal, None; G. Ozen, None; Z. Erturk, None; Y. Yalcinkaya, None; Z. Komesli, None; N. Inanc, None; P. Atagunduz, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Karabacak M, Unal AU, Ozen G, Erturk Z, Yalcinkaya Y, Komesli Z, Inanc N, Atagunduz P, Direskeneli H. Disease Severity and High Attack Frequency Under Colchicine Treatment Is Associated with Increased Carotid Intima Media Thickness in FMF [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disease-severity-and-high-attack-frequency-under-colchicine-treatment-is-associated-with-increased-carotid-intima-media-thickness-in-fmf/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-severity-and-high-attack-frequency-under-colchicine-treatment-is-associated-with-increased-carotid-intima-media-thickness-in-fmf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology